KR930001902A - 지방산의 약물의 제조방법 - Google Patents

지방산의 약물의 제조방법 Download PDF

Info

Publication number
KR930001902A
KR930001902A KR1019920013125A KR920013125A KR930001902A KR 930001902 A KR930001902 A KR 930001902A KR 1019920013125 A KR1019920013125 A KR 1019920013125A KR 920013125 A KR920013125 A KR 920013125A KR 930001902 A KR930001902 A KR 930001902A
Authority
KR
South Korea
Prior art keywords
fatty acid
essential fatty
series
day
acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019920013125A
Other languages
English (en)
Inventor
프레드릭 호로빈 데이비드
윈터 마이클
Original Assignee
카트리오나 프란세스 마르
에파몰 홀딩스 공공유한회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10698951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR930001902(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 카트리오나 프란세스 마르, 에파몰 홀딩스 공공유한회사 filed Critical 카트리오나 프란세스 마르
Publication of KR930001902A publication Critical patent/KR930001902A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Junction Field-Effect Transistors (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

내용 없음.

Description

지방산의 약물의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. AIDS 증상을 경감시키기 위한 또는 HIV 감염자의 AIDS 진전을 저지시키기 위한 약물의 제조, 또는 CD4 임파구 수를 증가시키기 위한 또는 HIV 감염자의 CD4 임파구수의 감소를 방지하기 위한 약물 제조를 위한 n-6 계열및/또는 n-3 계열의 하나 이상의 필수 지방산의 용도.
  2. 제1항에 있어서, 상기 산이 6-불포화화된 산, 특히 GLA(바람직한 n-6산), DGLA 및 AA, 그리고 n-3 계열의 SA, EPA(바람직한 n-3산), DPA, DHA로부터 선택되는 것을 특징으로 하는 상기 필수 지방산의 용도.
  3. 제1항 또는 제2항에 있어서, 상기 n-6및 n-3 계열 모두의 산이 선택되어지는 것을 특징으로 하는 상기 필수 지방산의 용도.
  4. 제3항에 있어서, GLA 및 EPA가 선택되어지는 것을 특징으로 하는 상기 필수지방산의 용도.
  5. 상기 선행항들중 어느 한 항에 있어서, n-3 계열의 EFAs에 대한 n-6 계열의 EFAs의 비율이 1:1 이상이고, 바람직하기로는 1.2 : 1 내지 6 : 1의 범위로 되는 것을 특징으로 하는 상기 필수지방산의 용도.
  6. 상기 선행항들 중 어느 한 항에 있어서, 상기 약물이 각 필수지방산 1mg내지 100g/일, 바람직하기로는 50mg 내지 10g/일, 더욱 바람직하기로는 200mgsowl 2g/일의 단위 복용량으로 투여되는 것을 특징으로 하는 상기 필수지방산의 용도.
  7. AIDS의 HIV 감염자에 있어서 n-6 계열 및/또는 n-3 계열의 하나 이상의 필수지방산을 투여하는 것을 특징으로 하는 AIDS로의 전진 또는 AIDS증상의 발현을 방지하기 위한, 또는 CD4 임파구 수를 증가시키거나 CD4 임파구수의 감소를 억제하기 위한 치료방법.
  8. 제7항에 있어서, 상기 투여된 필수지방산이 제2항 내지 제4항중 어느 항에 기술된 것으로 되는 것을 특징으로 하는 상기 치료방법.
  9. 제7항 또는 제항에 있어서, 상기 n-3 계열 EFAs에 대한 상기 n-6계열의 비가 1 : 1이상, 바람직하기로는 1.2 : 1내지 6 : 1의 범위로 되는 것을 특징으로 하는 상기 치료방법.
  10. 상기 제7항 내지 제9항중 어느 한 항에 있어서, 상기 약물이 각 필수지방산 1mg내지 100g/일, 바람직하기로는 50mg내지 10g/일, 더욱 바람직하기로는 200mg내지 2g/일의 단위 복용량으로 투여되는 것을 특징으로 하는 상기 치료방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019920013125A 1991-07-24 1992-07-23 지방산의 약물의 제조방법 Withdrawn KR930001902A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB91/16054.9 1991-07-24
GB919116054A GB9116054D0 (en) 1991-07-24 1991-07-24 Preparation of fatty acid medicaments

Publications (1)

Publication Number Publication Date
KR930001902A true KR930001902A (ko) 1993-02-22

Family

ID=10698951

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920013125A Withdrawn KR930001902A (ko) 1991-07-24 1992-07-23 지방산의 약물의 제조방법

Country Status (12)

Country Link
EP (1) EP0524796B1 (ko)
JP (1) JPH05194244A (ko)
KR (1) KR930001902A (ko)
AT (1) ATE120954T1 (ko)
AU (1) AU1968992A (ko)
CA (1) CA2073913A1 (ko)
DE (1) DE69202019D1 (ko)
FI (1) FI923357A7 (ko)
GB (1) GB9116054D0 (ko)
IE (1) IE922250A1 (ko)
NO (1) NO922936L (ko)
ZA (1) ZA925562B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214062A (en) * 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
US5674901A (en) * 1995-06-01 1997-10-07 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations
GB9211229D0 (en) * 1992-05-27 1992-07-08 Efamol Holdings Fatty acid treatment
GB9304746D0 (en) * 1993-03-09 1993-04-28 Scotia Holdings Plc Treatment of viral infections
GB9318611D0 (en) * 1993-09-08 1993-10-27 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US5767156A (en) * 1993-10-06 1998-06-16 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
US5856149A (en) * 1995-06-01 1999-01-05 Wisconsin Alumni Research Foundation Method of producing conjugated fatty acids
DE19611953A1 (de) * 1996-03-26 1997-10-02 Beiersdorf Ag Verwendung von ungesättigten Monocarbonsäuren gegen Superinfektionen
US7381413B1 (en) 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
ES2209658B1 (es) * 2002-12-05 2005-10-01 Proyecto Empresarial Brudy, S.L. Utilizacion del acido docosahexaenoico como principio activo para el tratamiento de la lipodistrofia.
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
RU2429718C2 (ru) * 2004-06-22 2011-09-27 Н.В. Нютрисиа Повышение целостности барьера у больных с вич
JP2006282644A (ja) * 2005-04-05 2006-10-19 Idemitsu Kosan Co Ltd 疲労回復剤
AU2007237685B2 (en) 2006-03-15 2012-08-09 Suntory Holdings Limited Compositions containing riboflavin and sesamin-class compounds
US8557764B2 (en) 2007-01-26 2013-10-15 The Regents Of The University Of Colorado, A Body Corporate Methods of modulating immune function
EP3342409A1 (en) 2007-03-15 2018-07-04 Suntory Holdings Limited Anti-fatigue agent
US9296776B2 (en) 2007-07-09 2016-03-29 Eastern Virginia Medical School Substituted nucleoside derivatives with antiviral and antimicrobial properties
US8653130B2 (en) 2007-09-19 2014-02-18 Suntory Holdings Limited Compositions containing sesamin-class compound(s) and arachidonic acid class compound(s)
JP2009073747A (ja) * 2007-09-19 2009-04-09 Suntory Ltd アラキドン酸を有効成分とする抗疲労剤
WO2020077420A1 (en) * 2018-10-16 2020-04-23 MOREIRA, Nivaldo José Extract of jatropha curcas seed oil

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4017979A1 (de) * 1990-06-05 1991-12-12 Meyer Lucas Gmbh & Co Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen

Also Published As

Publication number Publication date
AU1968992A (en) 1993-01-28
JPH05194244A (ja) 1993-08-03
IE922250A1 (en) 1993-01-27
ZA925562B (en) 1993-04-28
ATE120954T1 (de) 1995-04-15
NO922936D0 (no) 1992-07-23
EP0524796B1 (en) 1995-04-12
NO922936L (no) 1993-01-25
CA2073913A1 (en) 1993-01-25
EP0524796A1 (en) 1993-01-27
DE69202019D1 (de) 1995-05-18
FI923357L (fi) 1993-01-25
FI923357A7 (fi) 1993-01-25
GB9116054D0 (en) 1991-09-11
FI923357A0 (fi) 1992-07-23

Similar Documents

Publication Publication Date Title
US5116871A (en) Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis
KR940018089A (ko) 내부조직의 방사선 손상에 대한 예방 및 처치방법
CA2033823C (en) Combination of gla or dgla and selenium in psychiatric disorder treatment
BR9608785A (pt) Forma de dosagem oral contendo como um princípio ativo um ácido mega-3- poli insaturado uso de um ácido ómega-3-poli insaturado e processo de tratar inflamação intestinal
ATE157257T1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
CA2073913A1 (en) Preparation of fatty acid medicaments
DE3669106D1 (de) Pharmazeutische zusammensetzungen mit gehalt an flavanolignanen und phospholipiden als wirkstoffe.
KR900004338A (ko) 5-(4-클로로페닐)-2,4- 디메틸-3h-1,2,4- 트리아졸-3-티온을 이용한 혈소판증가증의 치료방법
KR930000114A (ko) 지방산을 이용한 치료
KR880003620A (ko) 치료용 합성물 및 치료법(Therapeutic Composition and Method)
KR940021056A (ko) 비루스 감염의 치료방법
KR910005858A (ko) 지방산 요법
RU94045866A (ru) Применение бисфенилалкилпиперазинов для лечения расстройств, вызванных злоупотреблением веществами, способ лечения
KR970701043A (ko) 항-염증성 및 감염 보호 효과를 갖는 세사민-기본 리그난(anti-inflammatory and infection protective effects of sesamin-based lignans)
KR920702225A (ko) 약학 조성물
RU93048868A (ru) Способ безопасного введения жирных кислот, его применение для лечения рака, инфекционных вирусных заболеваний и других нарушений
KR940003544A (ko) 지방산을 안전하게 투여하는 방법
KR890004705A (ko) 항바이러스성 제제
Schulof et al. Treatment of HTLV-III/LAV-infected patients with D-penicillamine
US5153221A (en) Method for the treatment of acquired immune deficiency syndrome
WO1994005300B1 (en) Use of rapamycin in the treatment of aids
ATE92756T1 (de) Mittel zur behandlung von keratose.
Patwardhan et al. Toxicity of Semecarpus anacardium extract
KR890009868A (ko) 1-메틸-β-옥소-α-(페닐카바모일)-2- 피롤프로피오니트릴의 트로메트아민염
KR890007728A (ko) 진통제 제조방법

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920723

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid